2018 May 23

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

The Genetics and Epigenetics of Myeloid Neoplasms group, headed by Drs Blanca Xicoy and Lurdes Zamora has led a study recently published in a letter to Leukemia Research. 

The Genetics and Epigenetics of Myeloid Neoplasms group, headed by Drs Blanca Xicoy and Lurdes Zamora has led a study recently published in a letter to Leukemia Research. 

The study has examined the treatment of Spanish patients with chronic myelomonocytic leukemia (CMML) classified as CMML-0 and CMML-1 according to the World Health Organization (WHO) 2008 criteria. 

CMML is a complex disease and it can present with a variety of characteristics, the prognosis can also vary widely between patients.   The WHO criteria are used around the world to stratify patients into different group; this helps medical teams provide the best treatments for each patient and also gives an indication of how the disease might progress.  In 2016 the WHO updated their criteria and proposed a new CMML-0 category.

This study showed that further dividing the previous WHO group CMML-1 into CMML-0 and CMML-1 did not provide more information about the outcome for CMML patients in Spain.   The authors examine previous studies carried out in Germany, which did show a difference, and comment that this might be due to other clinical and biological factors and not those used to define CMML-1 and CMML-0.

This type of work is very important for patients and doctors, as being able to separate patients into different groups according to the causes and characteristics of their form of the disease means they can receive a treatment that is likely to work for them.  Importantly, it also avoids patients undergoing unpleasant treatments that will not actually work in their case.  Dr Xicoy tells, us, “These are small steps, but we are moving towards a more personalized medicine for our patients.” 

Reference

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

Leukemia Research, Volume 70, July 2018, Pages 34-36 https://doi.org/10.1016/j.leukres.2018.05.003